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Estimates of seropositivity to a new infectious agent in a community are useful to public health. For
severe acute respiratory syndrome (SARS), the figures are conflicting. Herein, we screened 12,000 people
in a community stricken by SARS 10 months previously and found 53 individuals (0.44%) who had
immunoglobulin G antibodies to the SARS coronavirus (SARS-CoV) nucleocapsid (N) produced in
bacteria. However, only seven of these (group 1) had sera which also reacted with the native N antigen
expressed in SARS-CoV-infected Vero cells, N-transfected 293T cells, and tissues of infected SARS
patients. Of these, six individuals had had SARS previously. The remaining person, as well as the 46 other
individuals (group 2), were healthy and had no history of SARS. Group 1 antibodies recognized epitopes
located slightly differently in N from those of group 2 antibodies, and a mouse hybridoma antibody
resembling the former type was generated. Unusually, group 2 antibodies appeared to recognize cross-
reactive bacterial epitopes that presumably were posttranslationally modified in eukaryotes and hence
were probably not induced by SARS-CoV or related coronaviruses but rather by bacteria. The N antigen
is thus highly unique. The extremely low rate (0.008%) of asymptomatic SARS infection found attests to
the high virulence of the SARS-CoV virus.
Severe acute respiratory syndrome (SARS) emerged sud-
denly in 2003 but disappeared soon afterwards. It has left
behind a trail of questions, many of which have been promptly
answered. Indeed, a voluminous amount of valuable informa-
tion has been acquired regarding the etiological viral agent
(SARS coronavirus [SARS-CoV]) (7, 18, 20, 22), the patho-
genesis (10, 12, 21), the host immune response (15, 19, 26),
and, more recently, determinants of host resistance (2).
However, one question has remained inadequately an-
swered. This relates to the exposure of the general commu-
nity to SARS-CoV in places which have experienced an
outbreak of SARS. Determination of the exposure is usually
carried out by serological methods which detect antibodies
to the virus. Investigations conducted thus far are conflicting
regarding the prevalence of individuals in a community who
were seropositive but who did not have overt SARS previ-
ously (defined according to WHO guidelines). Based on this
definition—which considers subclinical or nonpneumonic
manifestations as asymptomatic—some studies found high
exposure rates (0.48% to 4.60%) (9, 27, 31, 32, 34) while
others found low (0.14% to 0.19%) (13, 16) to nil (1, 6, 9,
30) rates. Such differences may be due to the assay method
used (for example, Vero cell immunofluorescence [IFA]
versus enzyme-linked immunosorbent assay [ELISA]), the
type of antigen used for detection (for example, crude viral
lysate versus recombinant nucleocapsid [N] antigen), or the
population size sampled (87 to 1,621 people). Accurate in-
formation is desirable because a high exposure rate suggests
two possibilities: (i) the virus is not very virulent or (ii) the
virus cross-reacts antigenically with other viruses or micro-
organisms that are found commonly in the community. A
low exposure rate, on the other hand, suggests a highly
virulent virus that is unique and novel to the community.
This information is important not only for our general un-
derstanding of the pathogenic attributes and antigenic prop-
erties of the virus but also for public health measures and
the development of appropriate immunodiagnostics.
Herein, we report the exposure rate of the Hong Kong
community to SARS-CoV, determined after careful analysis of
seropositives first identified by initial screening. Hong Kong
had witnessed one of the first outbreaks of SARS in the world,
which started in February 2003 and ended in May 2003. A total
of 1,755 people were infected, of whom 298 died. The present
study was carried out 9 to 10 months after the disease started.
Serological screening was performed using an ELISA which
detects immunoglobulin G (IgG) antibodies to recombinant
SARS-CoV N antigens (15). We describe an unusual and im-
portant false-positivity problem associated with using antigens
produced in bacteria for detection and report, after correcting
for this shortcoming, the exceedingly low rate of exposure to
SARS in the Hong Kong community. The findings are useful
and applicable to other emerging infectious diseases such as
bird flu.
* Corresponding author. Mailing address: Clinical Immunology
Unit, The Chinese University of Hong Kong, Prince of Wales Hospital,
Shatin, Hong Kong. Phone and fax: (852) 2632 3031. E-mail: pllim
@cuhk.edu.hk.
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MATERIALS AND METHODS
Study cohort. Residents in the greater Hong Kong region were randomly
selected by computer to participate in the study in September to October 2003.
A total 50,000 households were invited, from which 12,000 people were recruited
with due consent. Of these, 56.3% were females and 87.6% were aged 18 years
and above.
Stored (20°C) sera of SARS patients admitted to the Prince of Wales Hos-
pital in Shatin, Hong Kong, obtained during the acute-convalescence phase (9 to
35 days after disease onset) of SARS were described previously (15).
SARS-CoV. Native viral antigens were extracted from Vero cells infected with
SARS-CoV (strain CUHK-W1; GenBank accession no. AY278554) by lysis in
HEPES buffer (pH 7.0) containing 0.2% Nonidet P-40 and 1 mmol/liter 1,4-
dithiothreitol (15). Recombinant viral antigens were produced as glutathione
S-transferase (GST) fusion proteins in Escherichia coli BL21 using pGEX-2T
(Amersham Bioscience) as a vector for the various N segments shown in Fig. 1
(15). The following forward (F) primers (containing a BamHI site, underlined)
and reverse (R) primers (containing an EcoRI site, underlined) were used to
synthesize the N segments by PCR from SARS-CoV cDNA: rNa (N-terminal N,
660 bp; F, 5-CGTGGATCCATGTCTGATAATGGACCCCAA-3; R, 5-CGA
TGAATTCCGAGGGCAGTTTCACCACCTCC-3), rNb (C-terminal N, 630
bp; F, 5-CGTGGATCCGGAGGTGGTGAAACTGCCCTC-3; R, 5-CGATG
AATTCCTGCCTGAGTTGAATCAGCAGA-3), rNb1 (N-terminal rNb, 321
bp; F, 5-CGTGGATCCGGAGGTGGTGAAACTGCCCTC-3; R, 5-CGATG
AATTCCGCGTGACATTCCAAAGAATGC-3), and rNb2 (C-terminal rNb,
330 bp; F, 5-CGTGGATCCGCATTCTTTGGAATGTCACGC-3; R, 5-CGA
TGAATTCCTGCCTGAGTTGAATCAGCAGA-3).
293T transient transfection. The rNb segment was synthesized from SARS-
CoV cDNA using the forward primer 5-CCACCATGGGAGGAGGTGGTGA
AACTGCCCTC-3 (containing a Kozak sequence, underlined) and the reverse
primer 5-TGCCTGAGTTGAATCAGCAGA-3 and ligated to the pcDNA3.1/
V5-His-TOPO vector (Invitrogen). Clones with the right insert orientation were
transiently transfected into 293T cells (ATCC) using Lipofectamine 2000 (In-
vitrogen) according to the manufacturer’s instructions. Forty microliters of trans-
fected cells was plated as droplet cultures on 12-well glass slides and incubated
overnight at 37°C in a humidified incubator infused with 5% CO2. The cells were
fixed with methanol-acetone (9:1) at 20°C for 10 min, air dried, and stored at
70°C until use.
Hybridoma production. BALB/c mice were hyperimmunized with purified
rNb-GST protein, and the spleen cells obtained from these animals were fused
with Sp2/0 myeloma cells (29). Hybridomas obtained were screened for reactivity
to rNb by ELISA (see below). Antibodies from selected clones were obtained
from the spent-culture supernatant and purified partially by ammonium sulfate
precipitation. In some cases, the antibodies were protein G selected and bio-
tinylated.
Isolation of rNa- and rNb-specific antibodies from human sera. Affinity ad-
sorbents were made by coupling the rNa or rNb recombinant protein (100 g) to
cyanogen bromide-activated Sepharose 4B (Sigma) (0.5 ml, 50% vol/vol). The
beads were blocked with 5% skim milk (2 h, room temperature [RT]), washed,
and incubated with the test serum (0.24 ml) at 4°C for 16 h on a roller-mixer.
After the beads were washed five times with phosphate-buffered saline (PBS)
containing 0.1% Tween 20, the bound antibodies were eluted by incubating the
beads with 0.1 M glycine-NaOH (pH 11.0) (0.5 ml) at RT for 5 min. The eluate
was dialyzed against PBS at 4°C overnight, concentrated by Centricon (Milli-
pore), and stabilized with 2.5% bovine serum albumin.
ELISA. Serum IgG activity in response to SARS-CoV N antigen was detected
by a direct ELISA which utilized a combination of bacterially produced rNa-GST
and rNb-GST proteins. The protocol used was essentially as described previously
(15). Basically, Immunon-2 plates (Dynex) were coated with equal proportions of
rNa (1 g/ml) and rNb (1 g/ml) in bicarbonate buffer (pH 9.6) overnight at 4°C.
The unknown serum (diluted 1:100) was incubated for 30 min at RT, while the
developing peroxidase-labeled antibody (goat anti-human IgG; BD Biosciences)
and substrate (3,3,5,5-tetramethylbenzidine) were each incubated for 15 min at
RT. Results were read at 450 nm in a Dynex MRX II reader. Cutoff for sero-
positivity was calculated as mean  2 standard deviations (SD) for 50 healthy
individuals. Other direct ELISAs were similarly performed using Immunon-2
plates coated with crude viral lysate (2 g/ml), rNa-GST (1 g/ml), or rNb-GST
(1 g/ml); the assay was developed with peroxidase-conjugated goat anti-human
Ig (IgM, IgG, or IgA specific; BD Biosciences) or with goat anti-mouse Ig (all
classes; BD Biosciences).
In the inhibition ELISA, serum antibody activity was detected by determining
the ability of the serum to block the binding of the indicator antibody (mAb13)
to the microplate-insolubilized antigen. The amount of mAb13 used was first
determined by titration of the antibody. Thus, in the test, the unknown serum
(diluted 1:100) was first incubated with the rNb-GST antigen for 16 h at 4°C.
Following a washing, biotinylated mAb13 was added, the serum was incubated at
37°C for 2 h, and the assay was subsequently developed with peroxidase-conju-
gated streptavidin (BD Biosciences) for a further 1.5 h at 37°C. Inhibition was
calculated as 1  [(ODtest  ODmax)/(ODmin  ODmax)], where ODmin is the
optical density (OD) without any inhibitor present (buffer control) and ODmax is
the OD value at highest inhibition using unlabeled mAb13 as the inhibitor.
IFA. SARS-CoV-infected Vero cells (Euroimmun), postmortem lung and in-
testinal tissues from SARS patients, and rNb-transfected 293T cells were used as
substrates for the detection of antibodies to SARS-CoV by IFA. With the
FIG. 1. Serological identification of community subjects exposed to
SARS-CoV. A) Map of SARS-CoV N protein showing the various
fragments (Na, Nb, Nb1, and Nb2) produced as GST fusion proteins in
bacteria used for serological detection. Numbers denote amino acid
numbering of protein. B) Purity of the recombinant fusion proteins
(rNa-GST and rNb-GST) isolated by affinity chromatography, sepa-
rated on 14% sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis gel, and stained by Coomassie blue. Starting material (crude lysate)
and molecular weight markers are also shown. C) ELISA results of
community subjects screened for IgG antibodies to a combination of
rNa-GST and rNb-GST. Comparative data of SARS patients using
sera obtained during acute-convalescence phase are shown (OD values
3.5 are plotted as 3.5). The shaded bar denotes the cutoff used to
differentiate between elevated and normal levels of antibodies. ‚, CS
individuals; ƒ, CSN individual; F, CN individuals.
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autopsy materials, sections (4 m thick) were prepared from 10% formalin-fixed,
paraffin-embedded blocks (25). Briefly, the cells or tissue sections were incubated
with the test serum or mouse monoclonal antibody (MAb) for 45 min, followed
by incubation (30 min) with fluorescein isothiocyanate-conjugated goat anti-
human Ig (all classes) (Euroimmun) or goat anti-mouse Ig (all classes) (Sigma)
(16, 25). With the tissue sections, images were captured individually in grayscale
by Spot Insight 4 (Nikon Eclipse 80) and then pseudocolored.
Western blot (WB) analysis. The detecting antigen (crude viral lysate, N
fragments) was heat denatured, separated on 10 to 14% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels, and transferred to poly-
vinylidene fluoride membrane (Bio-Rad) as described previously (15). The mem-
brane was blocked and incubated (1 h at RT) with the test serum or mouse MAb
and developed (1 h at RT) with horseradish peroxidase-conjugated goat anti-
human IgG (BD Biosciences) or goat anti-mouse Ig (all classes) (Sigma). Throm-
bin proteolysis of GST fusion proteins was performed by incubating 5 g of
protein with 2 units of thrombin (Amersham) overnight at RT.
Statistics. Comparison of groups was performed using the Mann-Whitney test
(PRISM; GraphPad Software), and a P  0.05 was considered significant.
RESULTS
Extremely low frequency of SARS seropositives found in
community, most of whose sera were unreactive with native
viral antigens. A total of 12,000 people were recruited from
the community to have their blood screened for the presence
of antibodies to the SARS virus. Detection was done by a
direct ELISA which detects IgG antibodies to viral N antigens.
These antigens were produced as two separate halves (rNa and
rNb) of the full-length protein in bacteria, each fused with the
bacterial protein GST (Fig. 1A). Purity analysis of the affinity-
isolated proteins used in the ELISA revealed no visible bacte-
rial contaminants present (Fig. 1B).
Fifty-three individuals (0.44%) were positive in the test using a
combination of rNa and rNb (Fig. 1C). The sera of these people
FIG. 2. Western blot results showing specificity of serum antibody activities of representative individuals from community groups (CS, CSN,
and CN) against SARS-CoV crude, native antigens or a recombinant GST-fused antigen (rNb). Numbers refer to identification of individuals used
throughout the text. A) Results for crude, native antigens separated on 10% gel. The reactivity of a SARS patient’s convalescence serum is included
for comparison. B) Specific reactivity of two individual CN sera to the viral protein moiety rather than the GST carrier shown in gel where the two
components of the fusion protein (rNb-GST) were separated on 14% gel following thrombin digestion. The leftmost panel shows locations of the
dye-stained components.
TABLE 1. Particulars of community seropositives
Group Designation No. ofindividuals Vero cell IFA titer(s) Clinical history
1 CS 6 1:80 (CS1), 1:320 (CS2, CS3), 1:640 (CS5,
CS6), 1:1,280 (CS4)
All had SARS previously; age range: 21–47 yr
(38.0  9.5 yr, mean  SD); 66.7% female
CSN 1 1:640 Healthy, no contact with SARS; age: 27 yr; female
2 CN 46 1:40 (all) All healthy; age range: 9–78 yr (40.7  15.3 yr,
mean  SD); 56.5% female
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were examined further for antiviral activity by Vero cell IFA.
Only seven (0.058%) were positive (Table 1). Of these, six (des-
ignated CS) had SARS infection previously and were hospital
patients. The remaining individual (designated CSN), a 27 year-
old female, as well as the 46 other individuals (designated CN)
who were IFA negative, had no history of SARS or had any
known contact with SARS patients previously (Table 1).
Sera from all 6 CS subjects and the single CSN individual, as
well as all 46 individuals from the CN group, were also exam-
ined by WB analysis using native viral antigens (extracted from
virally infected Vero cells) as the detecting antigen. While all
the CS sera and the CSN serum showed appropriate reactivity,
none of the CN sera were reactive (Fig. 2A). Taken together
with the IFA results, the findings indicate that CN subjects did
not really have antibodies directed to “native” SARS viral
antigens, unlike the CS individuals or CSN individual.
Community CN seropositives truly have antibodies reactive
with the bacterial recombinant N antigens, but the target
epitopes are different from those of antibodies derived from
SARS patients. We investigated whether the ELISA reactivity
seen with the CN sera when using the bacterial recombinant N
antigens was real and not an artifact of the assay used. Eight
CN individuals with the highest reactivity and serum availabil-
ity 0.1 ml were selected from the group for further studies.
From the WB analysis performed using thrombin-digested rNb
in which the N moiety was separated from GST, the results
FIG. 3. More-detailed characterization of antibody activities in representative community group subjects, based on reactivity to various rNb
subunits. A) ELISA results for individual subjects examined for type (IgM, IgA, or IgG) and specificity (crude native antigens or recombinant rNa
or rNb) of antibodies present. Shown are nine sera obtained from SARS patients during acute-convalescence phase, 6 CS sera, 1 CSN serum, 8
CN sera, and 5 sera from healthy subjects. The shaded area denotes negative reactivity, based on a value of mean plus 2 SD for healthy (non-SARS)
individuals. B) WB results for selected individuals showing reactivity of sera for rNb1-GST or rNb2-GST in 14% gel.
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clearly indicate that the serum reactivity was directed to N and
not to GST (or to epitopes created artificially at the bridge
between these fusion proteins) (Fig. 2B).
Further ELISA analysis demonstrated that the CN serum
reactivity was directed at rNb and not rNa (Fig. 3A). In addi-
tion, the reactivity was due to IgG antibodies and not IgM
or IgA.
Further subdivision of the Nb region into two halves (Nb1
and Nb2) (Fig. 1A) as individual GST fusion proteins revealed
that the WB reactivity of the CN sera was directed at rNb1 in
38% (3/8) of the subjects, at rNb2 in 50% (4/8), and at both
segments in 12% (1/8) of the cases (Fig. 3B).
In contrast, the anti-N antibodies found in the CS and CSN
subjects recognized different N epitopes. First, ELISA re-
vealed the reactivity of these antibodies with both rNa and
rNb, although reactivity with the latter was generally weaker
than with the former and was absent for rNb in the case of CSN
(Fig. 3A). The reactivity was due to IgG antibodies. For com-
parison, the reactive antibodies found in SARS patients within
a month of infection belonged to other classes besides IgG,
notably, IgM and IgA (Fig. 3A). IgA antibodies seemed to be
particularly abundant for rNb.
Second, in WB analysis, the antibodies from CS subjects
reacted only with rNb2, not rNb1 (5/6 cases), or with neither of
these (Fig. 3B). A slightly different specificity was seen with the
acute-convalescence sera of SARS patients, where reactivity
not only to rNb2 was seen but also, in some cases (2/4), to rNb1
(Fig. 3B).
Nb-purified antibodies from CS individuals differ in reac-
tivity from the Nb-specific antibodies of CN individuals. Since
the anti-N antibodies found in CS individuals recognized both
rNa and rNb, it was possible that the native antigen-binding
property of CS sera might belong solely to antibodies specific
for rNa and that the anti-rNb antibodies might not be reactive,
just like those of CN individuals. We investigated this possi-
bility by isolating the Nb-specific antibodies from CS sera.
FIG. 4. Specificity of rNa- or rNb-purified antibodies from CS or CN individuals and related mouse MAbs. A) ELISA results showing absence
of cross-reactivity between rNa and rNb used as the detecting antigen (coat) probed with rNa- or rNb-purified antibodies or with mAb13. B) IFA
results showing reactivity of CS-purified rNb-specific antibodies and mAb13 with SARS CoV-infected Vero cells (400) and the lung and intestinal
tissues (600) of SARS patients, and the lack of such reactivity by CN-purified rNb-specific antibodies. Inset shows Vero cells stained with
hematoxylin. For the human tissues, green denotes reagent antibody fluorescence, blue (or purple) denotes DNA (nuclear) staining, and red (or
orange) denotes nonspecific staining of red blood cells or the cytoplasm of other cells.
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Firstly, these antibodies displayed exquisite specificity for the
rNb fragment (Fig. 4A), whereas the rNa-specific antibodies
similarly purified bound only to rNa (Fig. 4A).
Strikingly, the Nb-purified antibodies of CS individuals re-
acted very well with the native viral antigens found in Vero
cells (Fig. 4B). In addition, these antibodies also stained the
viral antigens present in the lung and intestinal autopsy mate-
rials obtained from SARS-infected patients (Fig. 4B). Thus,
detached pneumocytes from the lung and surface enterocytes
of the intestine were occasionally stained. As expected, Nb-
purified antibodies similarly obtained from CN individuals
which showed ELISA activity against rNb-GST (data not
shown) did not react with either the Vero cells or the human
tissues (Fig. 4B).
Mouse monoclonal antibody generated is representative of
Nb-specific antibodies found in CS individuals. To understand
more about the Nb-specific antibodies, monoclonal antibodies
were generated from mice immunized with rNb. One hybrid-
oma antibody (mAb13, IgG1) was obtained; this antibody re-
sembled the Nb-specific antibodies of CS individuals (or SARS
patients) in the IFA staining reactions on Vero cells and hu-
man biopsy samples (Fig. 4B), as well as in ELISA (Fig. 4A)
and WB analysis (Fig. 5A) using either the Vero cell-derived
native antigens or rNb as the substrate. To find out whether
SARS patients would make antibodies to such an epitope,
acute-convalescence sera from 16 patients were examined for
the ability of these sera to block the binding of mAb13 (biotin
labeled) to rNb in an ELISA. Fourteen of these sera (87.5%)
were indeed found to be inhibitory (Fig. 5B). In contrast, none
of the 8 CN and 10 normal sera were reactive. The CSN serum
was also unreactive, but one-half (3/6) of the CS sera were
inhibitory. Considering the SARS patients as a group, the
reactivity of their serum was similar (P 	 0.224) to that of the
CS individuals, and both were significantly different from that
of healthy people (P  0.0001 and P 	 0.0075, respectively).
CN sera also fail to react with recombinant N antigens
expressed in eukaryotic cells. We reasoned that the CN sera
most probably recognized epitopes that were unique to bacte-
rial proteins and absent from eukaryotic proteins. To investi-
gate this possibility, we transfected 293T human kidney epi-
theloid cells with Nb cDNA and examined transient
transfectants with the CN sera. As expected, there was no
reactivity with these sera, whereas cells stained in parallel with
the CS sera or with mAb13 showed good cytoplasmic staining
(Fig. 6).
DISCUSSION
Based on the presence of IgG antibodies to the bacterially
produced SARS-CoV N antigen, 0.44% of the community in
Hong Kong were found seropositive for the SARS virus. Two
groups of seropositives could be identified based on the fine
specificity of the antibodies present: group 1, which resembles
SARS patients, and group 2, which does not. In the first group,
six of the seven individuals had had SARS previously. The
seventh person had no apparent SARS and hence may be
regarded as truly asymptomatic. We do not know how this
FIG. 5. Specificity of mAb13 and the prevalence of mAb13-like antibodies in human sera. A) WB results showing reactivity of MAb for rNb
and the native N antigen but not rNa. B) Inhibition ELISA determining the presence of mAb13-like antibodies in serum of various groups of
individuals. Antigen used, rNb-GST; indicator MAb used, biotinylated mAb13. Results indicate % inhibition of buffer control. Shaded area denotes
negative reactivity, based on mean plus 2 SD for healthy subjects.
FIG. 6. Examination of CN sera for reactivity with 293T cells tran-
siently transfected with rNb. IFA results (600) show reactivity of a CS
serum and mAb13 but not the CN serum. Also shown are transfected
cells stained with hematoxylin.
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young female got infected. Since it is unlikely that the antibod-
ies found in the 46 group 2 seropositives were elicited by the
SARS virus (see below), we estimate the asymptomatic expo-
sure rate of the community to the virus as 1 in 12,000 or
0.008%. This is extremely low. This suggests that SARS-CoV is
highly virulent, causing disease in virtually all people it infects
and inducing an antibody response in them. This is not sur-
prising in view of the high morbidity and mortality seen with
SARS (http://www.who.int/csr/sars) and is also consistent with
the behavior of a new emergent infectious agent. A similar
conclusion was reached previously when health care workers
who attended to SARS patients or their family members were
examined for exposure to the virus, although the asymptomatic
seropositive rates observed here, except for one study (19),
were considerably higher (0.14% to 4.60%) than ours (6, 9, 13,
16, 31). The high rates observed in these studies may be due to
the use of whole viral antigens or, as discussed below, the use
of bacterially produced N fragments (31). They may also be
due to the early sampling times used (within a few months of
disease outbreak), although IgG anti-N antibodies have been
reported to persist for as long as 16 months (17), longer than
our sampling period.
It is somewhat surprising that, using 400 to 938 stored sera of
healthy adults obtained 2 to 3 years prior to the SARS out-
break in Hong Kong, Woo et al. (27) and Zheng et al. (34)
found considerable cross-reactivity of these sera with SARS-
CoV. Thus, 4% and 0.75% seropositivities were observed in
the ELISA and WB analysis used, respectively, both utilizing a
bacterial full-length N protein (27). Questions have however
been raised over these estimates (31). We suspect the bacterial
antigen used (see below) may account for some degree of false
positivity. The importance of using an accurate detection sys-
tem was highlighted in a similar study by Yu et al. (32), who
found 11 seropositives (0.68%) from 1,621 healthy military
recruits in a pre-SARS period using an ELISA which utilized
whole SARS-CoV antigens, but none of these people were
positive in the viral neutralization test.
The low exposure rate found by us also suggests the lack of
antigenic cross-reactivity between SARS-CoV and other vi-
ruses found commonly in the Hong Kong population, namely,
HCoV-OC43 and HCoV-OC229E. A comparison of the N
sequence data among these viruses, which indicates low amino
acid homology between SARS-CoV and HCoV-OC43 (32.7%)
or HCoV-229E (21.3%), supports this contention. In accor-
dance, in a county in China adjacent to Hong Kong, Che et al.
(3) found that, whereas 97% to 99% of the healthy adults there
had IgG antibodies to the bacterially derived HCoV-229E and
HCoV-OC43 N antigens, only 2% were reactive with the
SARS-CoV counterpart. In another study using 13 or 14 pairs
of serum samples from American individuals infected with
HCoV-OC43 or HCoV-229E, which showed diagnostic rises
for these viruses, Ksiazek et al. (11) found no reactivity of these
sera with the SARS-CoV whole antigens when examined by
Vero cell IFA or ELISA. Contradictory results, however, were
observed by Woo et al. (28) in a repeat study using another
group of American sera (7 to 21 pairs), where 14.3% cross-
reactivity was found with both HCoV-OC43 and HCoV-229E.
In other studies which used ELISAs to detect SARS-CoV N
antigens, Che et al. (4) and Lau et al. (14) found no cross-
detection of the HCoV-229E or HCoV-OC43 N antigen. Di-
rect proof of the uniqueness of the SARS-CoV N antigen was
provided by cross-WB analysis using sera of rabbits immunized
with the various viral N antigens (3). Cross-reactivity, however,
was observed in earlier studies when animal sera made to
whole HCoV-229E virus were examined by SARS-CoV-in-
fected Vero cell IFA (11) or when sera raised against group I
coronaviruses, such as TGEV, CCoV, and FIPV, were used in
WB analysis against the SARS-CoV bacterial N antigen (23).
In the present study, the antibody activities of group 2 (CN)
individuals were found to be different from those of group 1 in
that these were absent when assayed against the native N
antigens expressed in Vero cells (Fig. 4B and 5A), in 293T cells
(Fig. 6), or in human tissues (Fig. 4B). The ELISA activities of
the group 2 sera were real, however, since the sera clearly
reacted with the bacterially produced N antigens in WB anal-
ysis (Fig. 3), particularly with the cleaved N antigen moiety
(Fig. 2B). These antibodies reacted specifically with rNb, but
not rNa (Fig. 3), and with both rNb1 and rNb2 (Fig. 3B). In
addition, Nb-specific antibodies could be purified from CN
sera which retained ELISA activity against rNb.
In contrast, the antibody activities of group 1 individuals
were directed at both rNa and rNb, particularly against rNb2 in
the latter. An rNb-specific MAb (mAb13) was found that re-
sembled these antibodies in IFA activity (Fig. 4B), as well as in
ELISA and WB analyses (Fig. 4A and 5A). Importantly, such
mAb13-like antibodies appeared to be dominantly and fre-
quently produced by SARS patients (Fig. 5B). Altogether, our
results suggest that SARS patients normally produce a great
heterogeneity of anti-N antibodies.
It thus appears that the group 1 antibodies recognize differ-
ent epitopes from those of group 2. Based on these differences,
we contend that the group 2 (CN) antibodies were not elicited
by SARS-CoV or by other coronaviruses. Rather, we argue
that these antibodies were induced by some bacterial proteins
that fortuitously share antigenic epitopes with the bacterially
derived N antigens. Proof of this, and what these bacterial
proteins are, will require more in-depth study. Since the anti-
bodies are of the IgG class only (Fig. 3A), they are presumably
the result of a distant infection.
Why the group 2 (CN) antibodies failed to react with the
native N antigen reflects the subtle differences between bacte-
rial and eukaryotic proteins. One possibility is the loss of frag-
ile epitopes from the eukaryotic protein as a result of host
enzymatic activity or during extraction. Although we have pre-
viously observed cleavage of the N protein in Vero cells (15),
loss of epitopes is not likely since the epitopes involved are not
localized at the C terminus of the protein or at the cleavage
points. It is also not likely that the group 2 antibodies recog-
nized cryptic epitopes that are absent in the eukaryotic pro-
teins since Western blotting was also used in the investigation.
It is more probable, however, that posttranslational modifica-
tion of the eukaryotic protein—which is absent in the bacterial
system—somehow masks the relevant epitope(s). Of the sev-
eral types of modification known, phosphorylation is a distinct
possibility. Thus, the N protein is known to be normally (33)
and extensively phosphorylated at multiple residues (24),
which involves many kinases that target the serine residue (24).
The native antigen is, however, not glycosylated.
The findings reported herein are important for the develop-
ment of appropriate immunodiagnostics for SARS. The em-
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ploy of 12,000 subjects in the present study provides a robust
evaluation of the specificity of the ELISA used. Even when
bacterial N antigens were used as the detecting antigens, when
46 individuals were falsely positive, the specificity of the test
was extremely high (99.62%). Specificity can conceivably be
enhanced even further if rNb is omitted from the test. Alter-
natively, the N antigens can be produced in eukaryotic cells
and used, but such production is more cumbersome and ex-
pensive than production in bacteria. Or, if the bacterial rNb is
to be kept, assaying for IgM or IgA antibodies instead of IgG
would avoid the cross-reactivity problem. Cases of the CSN
type, however, would be missed, but these numbers would be
small. An abundance of IgA antibodies appears to be produced
by SARS patients early in the disease, particularly to rNb (Fig.
3A). This suggests strong viral stimulation of the mucosal lym-
phoid tissues during the infection, similar to that seen with
poliovirus (8) or Epstein-Barr virus (5).
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